| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Dutogliptin Tartrate | REC-01; PHX-1149; PHX-1149T | Phase 3 Clinical | Phenomix | Diabetes Mellitus, Type 2; Leukemia, Myeloid, Acute; Myocardial Infarction; Renal Insufficiency; ST Elevation Myocardial Infarction | Details |
| Yogliptin | Phase 3 Clinical | Chengdu Easton Biopharmaceuticals Co Ltd, Sichuan Sunheal Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Empagliflozin/Sitagliptin Hydrochloride | DW1026C1; DW-1026C1; DW1026C2; DW-1026C2 | Phase 3 Clinical | Daewon Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
| Dapagliflozin formate/Linagliptin | IN-C009; AJU-A51 | Phase 3 Clinical | Aju Pharm Co Ltd, HK inno.N Corporation | Diabetes Mellitus, Type 2 | Details |
| DA5221-B2 | DA5221-B2 | Phase 3 Clinical | Dong-A ST Co Ltd | Diabetes Mellitus, Type 2 | Details |
| LID104 | LID104; LID-104 | Phase 3 Clinical | Ems | Diabetes Mellitus, Type 2 | Details |
| Empagliflozin/Metformin/Sitagliptin (Chong Kun Dang Pharmaceutical) | CKD-379 | Phase 3 Clinical | Chong Kun Dang Pharmaceutical Corp | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| TOTUM•63 | TOTUM-63 | Phase 3 Clinical | Valbiotis | Diabetes Mellitus, Type 2 | Details |
| Talabostat | VbP; PT-100; BXCL-701 | Phase 2 Clinical | Point Therapeutics | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Small Cell; CNS Embryonal Tumor; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Melanoma; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Solid tumours | Details |
| TQ-F3083 | TQ-F3083; CT-383 | Phase 2 Clinical | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Begelomab | SAND-26; BT 5/9 | Phase 2 Clinical | Adienne | Dermatomyositis; Graft vs Host Disease | Details |
| Singletine | DC-291407; DC-407; DC291407 | Phase 2 Clinical | Cisen Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Diabetes Mellitus, Type 2; Fatty Liver | Details |
| GCP-002 | EP-HMRG | Phase 2 Clinical | Goryo Chemical Inc | Esophageal Neoplasms | Details |
| Metformin/Dapagliflozin/Sitagliptin | GMRx4 | Phase 2 Clinical | George Medicines PTY Ltd, George Medicines UK Ltd | Diabetes Mellitus, Type 2 | Details |
| Bogliptin maleate | HL012MA | Phase 2 Clinical | East China University Of Science And Technology, Shandong Baiji Dichang Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Diabetes Mellitus, Type 2 | Details |
| CKD-393 | CKD-393 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Diabetes Mellitus, Type 2 | Details |
| Augliptin Hydrochloride | Phase 1 Clinical | Nanjing Changao Pharmaceutical Science And Technologyco Ltd, Shanghai Sun-Sail Pharmaceutical Science & Technology Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Evogliptin Tartrate | LY-05007 | Phase 1 Clinical | Dong-A Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
| Sitagliptin/Telmisartan | HDDO-16091 + HDDO-16092; HOB-077; HDDO-1609 | Phase 1 Clinical | Hyundai Pharmaceutical Co Ltd | Diabetes Mellitus; Hypertension | Details |
| TSL-0319 | TSL-0319 | Phase 1 Clinical | Jiangsu Tasly Diyi Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
| Prusogliptin/Dapagliflozin/Metformin | Phase 1 Clinical | Cspc Ouyi Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Vildagliptin and Metformin Hydrochloride Extended-Release Tablets(24h)(Taizhou Overseas Pharma) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Vildagliptin and Metformin Hydrochloride Extended-Release Tablets(Taizhou Overseas Pharma) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| Alogliptin and Metformin Hydrochloride Sustained-release Tablets(Taizhou Overseas Pharma) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| CTL-02 | CTL-02; CTL02 | Phase 1 Clinical | Celltrion Inc | Details | |
| Vildagliptin Sustained-release Tablets(Taizhou Overseas Pharma) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| AJU-A53 | AJU-A53 | Phase 1 Clinical | Aju Pharm Co Ltd | Diabetes Mellitus, Type 2 | Details |
| CKD-393(2) | CKD-393(2) | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Diabetes Mellitus, Type 2 | Details |
| ZHB-015 | ZHB-015; ZHB015; ZHB-C003 | Phase 1 Clinical | Zonhon Biopharma Institute Inc | Solid tumours | Details |
| CMR-316 | CMR316; CMR-316 | Phase 1 Clinical | The Calibr-Skaggs Institute for Innovative Medicines | Idiopathic Pulmonary Fibrosis; Pulmonary Disease, Chronic Obstructive; Respiratory Distress Syndrome, Adult | Details |
| Vildagliptin/Empagliflozin/Metformin Hydrochloride | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details | |
| CGT-2201 | CGT-2201 | Phase 1 Clinical | Cgenetech(Suzhou China) Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Empagliflozin/Metformin/Sitagliptin (Overseas Pharmaceuticals) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
| THDBH-100 | THDBH100; THDBH101 | Phase 1 Clinical | Wuxi Apptec(Shanghai) Co Ltd | Diabetes Mellitus, Type 2 | Details |
| WXSHC-071 | WXSHC-071 | Phase 1 Clinical | Dongbao Zixing (Hangzhou) Biological Medicine Co Ltd | Diabetes Mellitus, Type 2 | Details |
| REC-04 | Clinical | Recardio Inc | Cardiovascular Diseases | Details | |
| DASH inhibitor (Bach) | Clinical | Bach Biosciences LLC | Neoplasms | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Gemigliptin L-tartrate Sesquihydrate | LC-150444; LC-15-0444 | Approved | Lg Chemical Ltd | Gemiglo, Zemiglo | South Korea | Diabetes Mellitus, Type 2 | Lg Chemical Ltd | 2012-06-27 | Diabetes Mellitus, Type 2; Fasting; Hepatic Insufficiency | Details |
| Gemigliptin L-tartrate Sesquihydrate/Metformin Hydrochloride | Approved | Lg Chemical Ltd | ZemiMet SR | South Korea | Diabetes Mellitus, Type 2 | Lg Chemical Ltd | 2015-01-01 | Diabetes Mellitus, Type 2 | Details | |
| Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride | Approved | Handok Inc | Tenelia M SR | South Korea | Diabetes Mellitus, Type 2 | Handok Inc | 2015-11-03 | Diabetes Mellitus, Type 2 | Details | |
| Evogliptin | DA-1229; RNV-1001 | Approved | Dong-A Pharmaceutical Co Ltd | Sugarnon, Evodine, Suganon, SUGANON | South Korea | Diabetes Mellitus, Type 2 | Dong-A Pharmaceutical Co Ltd | 2015-10-02 | Aortic valve diseases; Diabetes Mellitus, Type 2; Liver Dysfunction; Renal Insufficiency | Details |
| Saxagliptin Hydrate | BMS-477118; BMS-477118-11; OPC-262 | Approved | Bristol-Myers Squibb Company | 安立泽, Onglyza | EU | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2009-07-31 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia | Details |
| Teneligliptin Hydrobromide Hydrate | MP-513 | Approved | Mitsubishi Tanabe Pharma | Tenglyn, Tenelia | Japan | Diabetes Mellitus, Type 2 | Mitsubishi Tanabe Pharma, Daiichi Sankyo Co Ltd | 2012-06-29 | Diabetes Mellitus, Type 2 | Details |
| Retagliptin Phosphate | SP-2086 Phosphate; SP 2086 | Approved | Jiangsu Hengrui Medicine Co Ltd | 瑞泽唐 | Mainland China | Diabetes Mellitus, Type 2 | Jiangsu Hengrui Medicine Co Ltd | 2023-06-27 | Diabetes Mellitus; Diabetes Mellitus, Type 2; Renal Insufficiency | Details |
| Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline | MK-0431J | Approved | Astellas Pharma Inc, Merck & Co Inc | Sujanu | Japan | Diabetes Mellitus, Type 2 | null | 2018-03-23 | Diabetes Mellitus, Type 2 | Details |
| Prusogliptin | DBPR-108 | Approved | National Health Research Institutes, Taiwan Shenlong Co Ltd | 善泽平 | Mainland China | Diabetes Mellitus, Type 2 | Cspc Ouyi Pharmaceutical Co Ltd | 2025-01-08 | Diabetes Mellitus, Type 2; Hepatic Insufficiency; Renal Insufficiency | Details |
| Linagliptin | BI-1356; BI-1356-BS | Approved | Boehringer Ingelheim International Gmbh | 欧唐宁, Ondero, Trajenta, Trayenta, Trazenta, Tradjenta | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim International Gmbh | 2011-05-02 | Albuminuria; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Diabetes Mellitus; Diabetes Mellitus, Type 2; Endocrine System Diseases; Glucose Metabolism Disorders; Hepatic Insufficiency; Hyperglycemia; Hypertension; Inflammation; Metabolic Diseases; Prediabetic State; Renal Insufficiency; Respiratory Tract Diseases; Schizophrenia; Ventricular Dysfunction, Left | Details |
| Rosuvastatin Calcium/Gemigliptin L-tartrate Sesquihydrate | Approved | Lg Chemical Ltd | ZemiStatin | South Korea | Diabetes Mellitus, Type 2; Dyslipidemias | Lg Chemical Ltd | 2017-07-31 | Diabetes Mellitus, Type 2; Dyslipidemias | Details | |
| Alogliptin Benzoate | SYR-322; TAK-322 | Approved | Takeda Pharmaceutical Co Ltd | Nesina, 尼欣那, Vipidia | Japan | Diabetes Mellitus, Type 2 | Takeda Pharmaceutical Co Ltd | 2010-04-06 | Acute Coronary Syndrome; Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Empagliflozin/Linagliptin/Metformin | Approved | Boehringer Ingelheim International Gmbh, Eli Lilly And Company | Trijardy XR | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim International Gmbh | 2020-01-27 | Diabetes Mellitus, Type 2 | Details | |
| Sitagliptin Phosphate/Metformin Hydrochloride | Approved | Merck & Co Inc | Velmetia, Janumet, 捷诺达 | United States | Diabetes Mellitus, Type 2 | Merck & Co Inc | 2007-03-30 | Diabetes Mellitus, Type 2 | Details | |
| Teneligliptin Hydrobromide Hydrate/Canagliflozin Hemihydrate | Approved | Daiichi Sankyo Co Ltd, Mitsubishi Tanabe Pharma Corp | Canalia | Japan | Diabetes Mellitus, Type 2 | Daiichi Sankyo Co Ltd, Mitsubishi Tanabe Pharma | 2017-07-03 | Diabetes Mellitus, Type 2 | Details | |
| Anagliptin/Metformin Hydrochloride | SK-1501 | Approved | Sanwa Kagaku Kenkyusho Co Ltd, Suzuken | Metoana | Japan | Diabetes Mellitus, Type 2 | Sanwa Kagaku Kenkyusho Co Ltd | 2018-09-21 | Diabetes Mellitus, Type 2 | Details |
| Vildagliptin/Metformin Hydrochloride | LMF-237 | Approved | Novartis Pharma Ag | 宜合瑞, Eucreas, EquMet, Zomarist, Icandra, Galvusmet | EU | Diabetes Mellitus, Type 2 | Novartis Europharm Ltd | 2007-11-14 | Diabetes Mellitus, Type 2 | Details |
| Sentagliptin Phosphate | CGT-8012 | Approved | Cgenetech(Suzhou China) Co Ltd | 盛捷维 | Mainland China | Diabetes Mellitus, Type 2 | Cgenetech(Suzhou China) Co Ltd | 2024-12-01 | Diabetes Mellitus, Type 2 | Details |
| Alogliptin Benzoate/Metformin Hydrochloride | CT-L01; CT-L-01 | Approved | Takeda Pharmaceutical Co Ltd | Vipdomet, Inisync, Kazano | United States | Diabetes Mellitus, Type 2 | Takeda Pharmaceuticals USA Inc | 2013-01-25 | Diabetes Mellitus, Type 2 | Details |
| Fultagliptin Benzoate | FCN-005; SAL067; SAL-067 | Approved | 信立汀 | Mainland China | Diabetes Mellitus, Type 2 | Shenzhen Salubris Pharmaceuticals Co Ltd | 2024-06-28 | Diabetes Mellitus, Type 2; Renal Insufficiency | Details | |
| Cofrogliptin | HSK7653; HSK-7653 | Approved | Liaoning Haisco Pharmaceutical Co Ltd, Sichuan Haisco Pharmaceutical Co Ltd | 倍长平 | Mainland China | Diabetes Mellitus, Type 2 | Haisco Pharmaceutical Group Co Ltd | 2024-06-18 | Diabetes Mellitus, Type 2; Glucose Intolerance; Renal Insufficiency | Details |
| Anagliptin | SK-0403; CWP-0403 | Approved | Sanwa Kagaku Kenkyusho Co Ltd | Suiny, Beskoa | Japan | Diabetes Mellitus, Type 2 | null | 2012-09-28 | Diabetes Mellitus, Type 2 | Details |
| Dapagliflozin Propanediol Monohydrate/Saxagliptin Hydrochloride | Approved | Astrazeneca Plc | Qtern | EU | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2016-07-15 | Diabetes Mellitus, Type 2 | Details | |
| Alogliptin Benzoate/Pioglitazone Hydrochloride | SYR-322-4833 BL | Approved | Takeda Pharmaceutical Co Ltd | Nesinaact, Oseni, Liovel, Incresync | Japan | Diabetes Mellitus, Type 2 | Takeda Pharmaceutical Co Ltd | 2011-07-01 | Diabetes Mellitus, Type 2 | Details |
| Sitagliptin Phosphate Monohydrate | ONO-5435A; ONO-5435; MK-0431; MK-431; L-000224715 | Approved | Merck Sharp & Dohme Corp | Ristaben, Xelevia, Tesavel, Glactiv, 捷诺维, Januvia, DIABIT-IS X | United States | Diabetes Mellitus, Type 2 | Merck & Co Inc | 2006-10-16 | Atherosclerosis; Carcinoma, Hepatocellular; Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Cystic Fibrosis; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gastroparesis; Glucose Intolerance; Graft vs Host Disease; Heart Failure; Hepatic Insufficiency; Hepatitis C; HIV Infections; Hyperlipidemias; Inflammation; Insulin Resistance; Kidney Failure, Chronic; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Metabolic Dysfunction-Associated Steatotic Liver Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prediabetic State; Psoriasis; Renal Insufficiency; Renal Insufficiency, Chronic | Details |
| Trelagliptin Succinate | TAK-472; SYR-472; SYR-111472; SYR-111472 succinate | Approved | Takeda Pharmaceutical Co Ltd | Zafatek | Japan | Diabetes Mellitus, Type 2 | Takeda Pharmaceutical Co Ltd | 2015-03-26 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Evogliptin Tartrate/Metformin Hydrochloride | DA-1229_01 | Approved | Dong-A Pharmaceutical Co Ltd | Sugamet XR | South Korea | Diabetes Mellitus, Type 2 | Dong-A Pharmaceutical Co Ltd | 2015-12-01 | Diabetes Mellitus, Type 2 | Details |
| Sitagliptin/Ertugliflozin | Approved | Pfizer Inc | Steglujan | United States | Diabetes Mellitus, Type 2 | Merck & Co Inc | 2017-12-19 | Diabetes Mellitus, Type 2 | Details | |
| Retagliptin Phosphate/Metformin Hydrochloride | HRX-0701; HRX0701 | Approved | Jiangsu Hengrui Medicine Co Ltd | 瑞霖唐 | Mainland China | Diabetes Mellitus, Type 2 | Shandong Shengdi Pharmaceutical Co Ltd | 2025-05-20 | Diabetes Mellitus, Type 2 | Details |
| Sitagliptin/Metformin Hydrochloride (Zydus Lifesciences) | Approved | Zydus Lifesciences Ltd | Zituvimet, ZITUVIMET | United States | Diabetes Mellitus, Type 2 | Zydus Lifesciences Ltd | 2023-11-03 | Diabetes Mellitus, Type 2 | Details | |
| Omarigliptin | MK-3102 | Approved | Merck & Co Inc | Marizev | Japan | Diabetes Mellitus, Type 2 | Merck Sharp & Dohme Corp | 2015-09-28 | Diabetes Mellitus; Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic | Details |
| Henagliflozin/metformin/retagliptin (Shandong Shengdi) | HR20031; HR-20031 | Approved | Shandong Shengdi Pharmaceutical Co Ltd | 瑞乐唐 | Mainland China | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Shandong Shengdi Pharmaceutical Co Ltd | 2025-10-21 | Diabetes Mellitus; Diabetes Mellitus, Type 2 | Details |
| Teneligliptin/Pioglitazone | Approved | Glenmark Pharmaceuticals Ltd | Zita Plus Pio | India | Diabetes Mellitus, Type 2 | Glenmark Pharmaceuticals Ltd | 2022-04-25 | Diabetes Mellitus, Type 2 | Details | |
| Dapagliflozin Propanediol Hydrate/Sitagliptin Phosphate Hydrate | SID-1903; DW-6012 | Approved | Dong Wha Pharm Co Ltd | Sidapvia | South Korea | Diabetes Mellitus, Type 2 | Dong Wha Pharm Co Ltd | 2023-06-30 | Diabetes Mellitus, Type 2; Myocardial Infarction; ST Elevation Myocardial Infarction | Details |
| Metformin Hydrochloride/Sitagliptin Hydrochloride | Approved | Sandoz Bv | EU | Sandoz Bv | 2019-12-10 | Details | ||||
| Sitagliptin Tartrate | Approved | Heumann Pharma GmbH & Co Generica KG | Sitagliptin Heumann 25 mg Filmtabletten | EU | Heumann Pharma GmbH & Co Generica KG | 2020-12-14 | Diabetes Mellitus, Type 1; Diabetic Nephropathies; Metabolic Dysfunction-Associated Steatotic Liver Disease; Parkinson Disease | Details | ||
| Sitagliptin Hydrochloride | Approved | Laboratorios Alter Sa | Spain | Diabetes Mellitus, Type 2 | Laboratorios Alter Sa | 2019-03-06 | Diabetes Mellitus, Type 2; Polycystic Ovary Syndrome | Details | ||
| Gemigliptin/Dapagliflozin | Approved | Lg Chemical Ltd | Zemidapa | South Korea | Diabetes Mellitus, Type 2 | Lg Chemical Ltd | 2022-06-21 | Diabetes Mellitus, Type 2 | Details | |
| Linagliptin/Metformin Hydrochloride | GC2129A; GC-2129-A; DW6013 | Approved | Boehringer Ingelheim International Gmbh | Jentadueto Xr, Trajenta Duo, Jentadueto, 欧双宁 | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim International Gmbh | 2012-01-30 | Diabetes Mellitus, Type 2 | Details |
| Linagliptin/Empagliflozin | BI 1356/BI 10773; BI 10773/linagliptin; BI 1356/empagliflozin; Empagliflozin/BI 1356; Linagliptin/BI 10773; BI 10773/BI 1356 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Tradiance, Glyxambi, Esgliteo | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim International Gmbh | 2015-01-30 | Cardiovascular Diseases; Diabetes Mellitus, Type 2 | Details |
| Vildagliptin | LAF-237; DSP-7238; LAF-237A; NVP-LAF-237 | Approved | Novartis Pharma Ag | 佳维乐, Equa, Jalra, Galvus, Gliptus, Xiliarx | EU | Diabetes Mellitus, Type 2 | Novartis Europharm Ltd | 2007-09-25 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dyslipidemias; Insulin Resistance; Prediabetic State; Renal Insufficiency; Schizophrenia | Details |
| Saxagliptin Hydrochloride/Metformin Hydrochloride | Approved | Astrazeneca Plc | 安立格, Kombiglyze Xr, Komboglyze | EU | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2010-11-05 | Diabetes Mellitus, Type 2 | Details |